NASDAQ · VOR
Vor Biopharma Inc.
Healthcare · Biotechnology
$19.37▼ 11.95% ($2.63)at close
Pre-market$19.38▲ 0.04%4:00 AM ET
Market cap
$1.05B
P/E
1.68
EPS (TTM)
$11.56
Next earnings
Nov 12, 2026
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Need reported operating working-capital balances or comparable changes in working capital to forecast reinvestment; an unknown requirement cannot be treated as zero.
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
Data notes
Fewer than two comparable annual revenue periods are available, so growth is taken from the latest quarterly year-over-year figure without the annual cross-check.
- 10-yr revenue CAGR
- —
- Ending operating margin
- —
- Discount rate
- —
USD · Price used $19.37 · Price Sep 23, 8:00 PM UTC
Your case starts from the selected scenario.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 38.08% over the last year. Free cash flow declined 23.69% over the trailing twelve months.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Free cash flow fell 23.69% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer.
Market multiples
Stock splits
Every 20 shares became 1
Profitability & growth
Analyst consensus
10
Buy
3
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 12, 2026
Q4 FY26 · EPS est -$0.81 · Revenue est —
View
Institutional Sentiment
Vor Biopharma Inc. · VOR
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.